# Dexcom, Inc. (NASDAQ: DXCM), San Diego, CA – FDA Inspections

Source: https://www.keypedia.com/companies/dexcom-inc/e6b9b288-fede-4673-88ef-fd37fc036366

> Inspection records and compliance data for Dexcom, Inc. in San Diego, California. 11 FDA inspections on record (3 OAI), 2 Form 483s, 3 warning letters, last inspected November 07, 2024. Publicly traded as NASDAQ: DXCM.

---

## Details

- Name: Dexcom, Inc.
- FEI Number: 3004753838
- Address Line 1: 6340 Sequence Dr
- City: San Diego
- State: California
- Zip Code: 92121
- Country Name: United States
- Address: 6340 Sequence Dr, San Diego, California 92121, United States
- Country: United States

## Stock

- Stock ticker: DXCM
- Exchange: NASDAQ
- Share price: $81.39
- Market cap: $30.4B
- Price as of: November 13, 2026

## Related Documents

- [483 - Dexcom, Inc. - Unknown Date](https://www.keypedia.com/records/483/dexcom-inc/d19fd6fe-0cac-4e87-ac09-00ff141b0d77) — source: FDA, date: Invalid Date
- [483 - Dexcom, Inc. - 2024-11-07](https://www.keypedia.com/records/483/dexcom-inc/b46e42e3-138e-4bd3-b8ec-f506013684e3) — source: FDA, date: November 7, 2024
- [WARNING_LETTER - Dexcom, Inc. - 2024-11-07](https://www.keypedia.com/records/warning_letter/dexcom-inc/f1c80d4f-168c-4052-9259-d522c918a7e1) — source: FDA, date: November 7, 2024
- [FDA Inspection 1250922 - Dexcom, Inc. - 2024-11-07](https://www.keypedia.com/records/fda_inspections/dexcom-inc/6f6155e1-7e42-4c29-b575-fd65eb84e9fa) — classification: Official Action Indicated (OAI), source: FDA, date: November 7, 2024
- FDA Inspection 1250922 - Dexcom, Inc. - 2024-11-07 — classification: No Action Indicated (NAI), source: FDA, date: November 7, 2024
- FDA Inspection 1250922 - Dexcom, Inc. - 2024-11-07 — classification: No Action Indicated (NAI), source: FDA, date: November 7, 2024
- FDA Inspection 1250922 - Dexcom, Inc. - 2024-11-07 — classification: Official Action Indicated (OAI), source: FDA, date: November 7, 2024
- FDA Inspection 1220386 - Dexcom, Inc. - 2023-09-29 — classification: No Action Indicated (NAI), source: FDA, date: September 29, 2023
- FDA Inspection 1220386 - Dexcom, Inc. - 2023-09-29 — classification: No Action Indicated (NAI), source: FDA, date: September 29, 2023
- [483 - Dexcom, Inc. - 2021-09-17](https://www.keypedia.com/records/483/dexcom-inc/a7ffd4a6-1d14-4e61-8684-27c55465e952) — source: FDA, date: September 17, 2021
- FDA Inspection 1152320 - Dexcom, Inc. - 2021-09-17 — classification: No Action Indicated (NAI), source: FDA, date: September 17, 2021
- FDA Inspection 1152320 - Dexcom, Inc. - 2021-09-17 — classification: Voluntary Action Indicated (VAI), source: FDA, date: September 17, 2021
- [EIR - Dexcom, Inc. - 2018-02-16](https://www.keypedia.com/records/eir/dexcom-inc/b0b39a1f-ca22-44c6-bfa7-3fc28a266211) — source: FDA, date: February 16, 2018
- FDA Inspection 1041434 - Dexcom, Inc. - 2018-02-16 — classification: Voluntary Action Indicated (VAI), source: FDA, date: February 16, 2018
- [FDA Inspection 1041434 - Dexcom, Inc. - 2018-02-16](https://www.keypedia.com/records/fda_inspections/dexcom-inc/e2472c3d-9870-4181-b652-d7105450f55b) — classification: Voluntary Action Indicated (VAI), source: FDA, date: February 16, 2018
- [EIR - Dexcom, Inc. - 2016-03-29](https://www.keypedia.com/records/eir/dexcom-inc/8186d170-c81e-475a-8f4c-33e01a4ec90a) — source: FDA, date: March 29, 2016
- [EIR - Dexcom, Inc. - 2015-04-21](https://www.keypedia.com/records/eir/dexcom-inc/13ee6670-e8dd-4eef-bc86-8d9ab3c43f82) — source: FDA, date: April 21, 2015
- [WARNING_LETTER - Dexcom, Inc. - 2013-11-07](https://www.keypedia.com/records/warning_letter/dexcom-inc/152815a0-df40-4586-9264-d83af45f80c1) — source: FDA, date: November 7, 2013
- [WARNING_LETTER - Dexcom, Inc. - 2010-02-08](https://www.keypedia.com/records/warning_letter/dexcom-inc/9e86a827-0355-4269-852e-37055f547f35) — source: FDA, date: February 8, 2010

## Related Companies

- [Olympus Corporation of the Americas](https://www.keypedia.com/companies/olympus-corporation-of-the-americas/b2a67c6c-b9f4-407d-a8b3-0720c4faab45)
- [Lusys Laboratories, Inc.](https://www.keypedia.com/companies/lusys-laboratories-inc/348b7ce4-cdf8-44e0-abf5-ff62a64182ac)
- [DynaFlex](https://www.keypedia.com/companies/dynaflex/a805d418-c220-4dcf-8f82-08ee4c075100)
- [Cognivue Inc.](https://www.keypedia.com/companies/cognivue-inc/12d584b2-cd96-4b0f-9d92-6efb90102a80)
- [Fresenius Kabi USA, LLC](https://www.keypedia.com/companies/fresenius-kabi-usa-llc/f0976e16-40e3-475b-8dc0-c9e721658b4a)
- [Seriously Clean, Ltd.](https://www.keypedia.com/companies/seriously-clean-ltd/fa2a25fb-25a9-4081-a09d-17c0715d6830)
- [ISOVAC Products, LLC](https://www.keypedia.com/companies/isovac-products-llc/e76a5501-93ec-497f-8af4-92d23bb2e5f9)
- [bioMerieux, Inc.](https://www.keypedia.com/companies/biomerieux-inc/0e90e065-1a28-4743-9958-555322a42a36)
- [CEP Bio-Coat, LLC](https://www.keypedia.com/companies/cep-bio-coat-llc/3f1e2dce-40c6-4608-94a6-1955bfe593b9)
- [Morgan Newton Comp.](https://www.keypedia.com/companies/morgan-newton-comp/6944980a-e15f-4d2e-9a6a-e141f444bf70)

## Related Officers

- [Director](https://www.keypedia.com/people/alonza-e-cruse/650e3631-3f99-45f7-863e-3a35c44be485)
- [Raymond W. Brullo](https://www.keypedia.com/people/raymond-w-brullo/c3500ac9-8d22-4c49-b416-8786d548eb93)
- [Shaquenta Perkins](https://www.keypedia.com/people/shaquenta-perkins/00369bbd-5784-42c2-847e-202c8b1b87a2)
- [recipient](https://www.keypedia.com/people/kevin-r-sayer/01ea55ae-dc6b-4a14-b951-8e753d804500)